The RAGE Inhibitor TTP488 (Azeliragon) Improves Diabetic Bladder Dysfunction in Leptin-Deficient Obese Mice

The advanced glycation end product (AGE)-RAGE axis has been implicated in the pathophysiology of diabetic bladder dysfunction (DBD). However, no previous studies have explored the effects of RAGE blockade on this condition. Here, we explored the effects of the selective RAGE inhibitor TTP488 (azeliragon) at the functional and molecular levels of bladder dysfunction in <i>ob</i>/<i>ob</i> leptin-deficient mice. Female B6.V-Lep ob/JUnib (<i>ob</i>/<i>ob</i>) and wild-type (WT) C57BL/6 mice were used as lean controls. Treatment with TTP488 in <i>ob</i>/<i>ob</i> mice resulted in no changes in body weight, fasting glucose, or insulin resistance; however, it reduced total AGE and MG-H1 levels without altering RAGE levels in bladder tissues. TTP488 normalized glyoxalase-1, glutathione reductase, glutathione peroxidase, and superoxide dismutase activities in bladder tissues. Marked increases in collagen intensity were also observed in <i>ob</i>/<i>ob</i> mice, an effect fully reversed by TTP488 treatment. TTP488 reduced total void volume, volume per void, and ex vivo bladder contractility in response to electrical-field stimulation and carbachol. Our finding that TTP488 mitigates DBD in <i>ob</i>/<i>ob</i> mice supports the proposal that RAGE blockade could serve as a promising therapeutic strategy for managing DBD.